Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform

April 6 (Reuters) - Alphabet Inc GOOGL.O:

• STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORM

• STIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURES

• STIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100